Payment overview · 2025
General Payments
$122.20
6 reported records · 5 companies
Healthcare provider profile · identity verified
John Yule Tsou, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HUDSON, NY · NPI 1750348983
Verified facts
What the public records show
CMS Open Payments records show John Yule Tsou, M.D. received $122.20 in general payments during 2025 across 6 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 34.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rexulti.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $42.60 | 34.9% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.87 | 17.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.64 | 16.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.33 | 15.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.76 | 15.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $122.20 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $42.60 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.64 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.64 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 84 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 104 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 15 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
104 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 556 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 368 | 76 |
| Atorvastatin Calcium | Atorvastatin Calcium | 354 | 84 |
| Eliquis | Apixaban | 318 | 37 |
| Metformin Hcl | Metformin Hcl | 299 | 70 |
| Lisinopril | Lisinopril | 240 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 219 | 44 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 172 | 50 |
| Trazodone Hcl | Trazodone Hcl | 158 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 157 | 23 |
| Furosemide | Furosemide | 155 | 37 |
| Omeprazole | Omeprazole | 155 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 149 | 27 |
| Losartan Potassium | Losartan Potassium | 131 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 131 | 21 |
| Sertraline Hcl | Sertraline Hcl | 128 | 23 |
| Mirtazapine | Mirtazapine | 119 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 106 | 26 |
| Rexulti | Brexpiprazole | 104 | suppressed |
| Potassium Chloride | Potassium Chloride | 103 | 25 |
| Divalproex Sodium | Divalproex Sodium | 102 | 15 |
| Gabapentin | Gabapentin | 100 | 22 |
| Simvastatin | Simvastatin | 90 | 24 |
| Risperidone | Risperidone | 89 | 11 |
| Alprazolam | Alprazolam | 87 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 85 | 14 |
| Ozempic | Semaglutide | 84 | 15 |
| Allopurinol | Allopurinol | 75 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 67 | 13 |
| Glipizide | Glipizide | 66 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 65 | 15 |
| Novolog Flexpen | Insulin Aspart | 63 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 59 | 11 |
| Finasteride | Finasteride | 57 | suppressed |
| Januvia | Sitagliptin Phosphate | 56 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 17 |
| Enalapril Maleate | Enalapril Maleate | 55 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 12 |
| Lorazepam | Lorazepam | 52 | 18 |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | suppressed |
| Bupropion Xl | Bupropion Hcl | 49 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 49 | 49 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 48 | suppressed |
| Carvedilol | Carvedilol | 47 | suppressed |
| Methimazole | Methimazole | 45 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 44 | suppressed |
| Famotidine | Famotidine | 42 | 12 |
| Olanzapine | Olanzapine | 42 | suppressed |
| Pregabalin | Pregabalin | 42 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | suppressed |
| Synthroid | Levothyroxine Sodium | 40 | 11 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 36 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | 14 |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Tradjenta | Linagliptin | 34 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 33 | 11 |
| Tramadol Hcl | Tramadol Hcl | 33 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 31 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Latanoprost | Latanoprost | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Repaglinide | Repaglinide | 30 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Prednisone | Prednisone | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Novolog | Insulin Aspart | 26 | suppressed |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 20 |
| Atenolol | Atenolol | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Risperidone Odt | Risperidone | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Armour Thyroid | Thyroid,pork | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 19 | 16 |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 18 |
| Pentips Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 12 |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Oxycontin | Oxycodone Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Securesafe Pen Needle | Pen Needle, Diabetic, Safety | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Alprazolam Er | Alprazolam | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Xanax | Alprazolam | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $122.20 · 6 records | Otsuka America Pharmaceutical, Inc. | FREESTYLE LIBRE 3, GVOKE HYPOPEN, MOUNJARO, Ozempic, REXULTI, Rybelsus, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error